{
  "paper_id": "PMC10362395",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362395/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Schematic representation of an antibody-drug conjugate",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10362395/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/bf209a292972/gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Mechanism of action of antibody-drug conjugates",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10362395/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/59c5bb44c6ed/gr2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Chemical structures of disclosed drug-linker moieties used in antibody-drug conjugates against HER2-positive breast cancer",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10362395/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/142a5465e83e/gr3.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Antibody, payload, and linker types\nTypes of antibody (A), payload (B), and linker (C) used in antibody-drug conjugates under development for patients with HER2-positive breast cancer in clinical trials. mAb, monoclonal antibody.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10362395/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ec/10362395/f0eb0988aa06/gr4.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Anatomy of ADCs\nADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ADCs are composed of four key components, including (1) a target antigen, (2) an antibody construct, (3) a cytotoxic agent (generally known as a payload), and (4) a linker (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neighboring cancer cells may also be killed when ADCs are designed to stimulate the release of the payloads into the extracellular space or once free drugs are released into the tumor environment through the dying cell, in a process known as the bystander effect (Figure 2).19,20,21,22,23.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 3 also shows chemical structures of disclosed linker-drug moieties used in ADCs approved and under clinical trials for the treatment of HER2-positive breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Trastuzumab, or trastuzumab derivatives, was the most popular mAb, used in approximately 60% of the disclosed ADCs under clinical investigation against HER2-positive breast cancer (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Approximately 14% and 10% of the ADCs utilize DNA-damaging agents (such as PBDs, duocarmycins, and doxorubicins) and immunomodulators (such as TLR agonists), respectively (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The cleavable linkers (particularly vc) are the most commonly used linkers in the ADCs under clinical investigation against HER2-positive breast cancer (Figure 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 4,
    "claims_count": 62,
    "images_downloaded": 4,
    "tables_filtered": 4
  }
}